Eton Pharmaceuticals (NASDAQ:ETON) Now Covered by Analysts at B. Riley

B. Riley initiated coverage on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a report released on Friday morning, Marketbeat reports. The firm issued a buy rating and a $21.00 target price on the stock.

Several other brokerages have also recently issued reports on ETON. HC Wainwright lifted their price objective on Eton Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, January 6th. Craig Hallum lifted their price target on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday.

Eton Pharmaceuticals Trading Up 11.9 %

Shares of Eton Pharmaceuticals stock opened at $13.44 on Friday. The company has a 50-day moving average of $11.64 and a two-hundred day moving average of $7.35. The stock has a market cap of $350.13 million, a PE ratio of -61.09 and a beta of 1.38. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $15.00.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ETON. Wasatch Advisors LP acquired a new position in shares of Eton Pharmaceuticals in the third quarter worth $1,431,000. Thompson Siegel & Walmsley LLC acquired a new position in Eton Pharmaceuticals in the 2nd quarter valued at about $420,000. Aristides Capital LLC purchased a new position in Eton Pharmaceuticals in the 2nd quarter valued at about $658,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after buying an additional 41,469 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.